Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 125 points (-0.8%) at 16,333 as of Tuesday, Jan. 21, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,733 issues advancing vs. 1,234 declining with 157 unchanged. The Health Services industry currently is unchanged today versus the S&P 500, which is down 0.1%. Top gainers within the industry include Edwards Life ( EW), up 1.7%, and Fresenius Medical Care AG & Co. KGaA ( FMS), up 1.0%. On the negative front, top decliners within the industry include Community Health Systems ( CYH), down 3.9%, Mindray Medical International Limited ADR r ( MR), down 3.4%, Universal Health Services ( UHS), down 2.7% and Baxter International ( BAX), down 0.5%. TheStreet would like to highlight 5 stocks pushing the industry higher today: 5. DaVita HealthCare Partners ( DVA) is one of the companies pushing the Health Services industry higher today. As of noon trading, DaVita HealthCare Partners is up $0.50 (0.8%) to $65.33 on light volume. Thus far, 773,525 shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $64.78-$65.55 after having opened the day at $65.39 as compared to the previous trading day's close of $64.83. DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $13.8 billion and is part of the health care sector. The company has a P/E ratio of 24.4, above the S&P 500 P/E ratio of 17.7. Shares are up 2.3% year-to-date as of the close of trading on Friday. Currently there are 9 analysts who rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 4 rate it a hold. TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full DaVita HealthCare Partners Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.